MYSTIC

News

Blow for AstraZeneca as cancer combination fails

After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.

News

Soriot commits to AstraZeneca as shares slide

AstraZeneca (AZ) has tried to put a brave face on today’s news that its immunotherapy combination is unlikely to be a contender in lung cancer.

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks